Rhythm Pharmaceuticals Inc (RYTM): Next-Year EPS Estimate 78.47%
As of 2026-11-12, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 78.47%. Featured in 3 EPS revision reports, most recently on 2026-11-06.
On 2026-11-09, analyst consensus for RYTM's next-year EPS growth shifted from 80.94% to 78.47% — a negative change of 2.47 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at -54.37%.
What's Driving This
The primary driver is the analysts' upgrade of next-year EPS growth estimate from 74.71% to 77.75% on August 5, 2026. This follows positive clinical data presented at ENDO 2026, including interim Phase 2 results for setmelanotide in Prader-Willi syndrome, which likely prompted the upward revision. The stock continued to gain as the estimate edged up further to 77.78%, reflecting sustained momentum.
Generated 2026-08-13 from news as of 2026-08-13
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 78.47%
- EPS growth this year
- -54.37%
- EPS next quarter (est)
- -$2.59
- Last price
- $109.86
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 78.47% | -54.37% | -$2.59 | $109.86 |
| 2026-11-11 | 78.47% | -54.37% | -$2.59 | $112.16 |
| 2026-11-10 | 78.47% | -54.37% | -$2.59 | $113.95 |
| 2026-11-09 | 78.47% | -54.37% | -$2.59 | $113.94 |
| 2026-11-07 | 80.94% | -54.37% | -$2.47 | $112.28 |
| 2026-11-06 | 80.94% | -54.37% | -$2.47 | $112.28 |
| 2026-11-05 | 80.28% | -46.20% | -$2.23 | $105.02 |
| 2026-11-04 | 80.28% | -46.20% | -$2.23 | $110.68 |
| 2026-11-03 | 72.46% | -16.55% | -$1.37 | $86.44 |
| 2026-11-02 | 78.07% | 5.29% | -$0.71 | $93.44 |
| 2026-10-31 | 78.07% | 5.29% | -$0.71 | $92.57 |
| 2026-10-30 | 78.07% | 5.29% | -$0.71 | $92.57 |
| 2026-10-29 | 78.07% | 5.29% | -$0.71 | $93.07 |
| 2026-10-28 | 78.06% | 5.28% | -$0.71 | $91.97 |
| 2026-10-27 | 78.06% | 5.28% | -$0.71 | $92.18 |
| 2026-10-26 | 78.06% | 5.28% | -$0.71 | $89.47 |
| 2026-10-23 | 78.06% | 5.28% | -$0.71 | $89.27 |
| 2026-10-22 | 78.06% | 5.28% | -$0.71 | $90.90 |
| 2026-10-21 | 78.06% | 5.28% | -$0.71 | $88.62 |
| 2026-10-20 | 78.06% | 5.28% | -$0.71 | $90.20 |
| 2026-10-19 | 78.06% | 5.28% | -$0.71 | $88.23 |
| 2026-10-16 | 78.06% | 5.28% | -$0.71 | $86.17 |
| 2026-10-15 | 77.96% | 5.08% | -$0.71 | $87.97 |
| 2026-10-14 | 78.18% | 5.08% | -$0.71 | $86.71 |
| 2026-10-13 | 78.18% | 5.08% | -$0.71 | $86.61 |
| 2026-10-12 | 78.18% | 5.08% | -$0.71 | $89.82 |
| 2026-10-11 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-10 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-09 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-08 | 78.21% | 4.75% | -$0.72 | $89.64 |
Reports Featuring RYTM
Recent News
- Rhythm Pharmaceuticals Beats As Hypothalamic Obesity Launch Accelerates, But New Debt And LG Chem Payments Recast The StoryEarnings Whispers
- Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License AgreementGlobeNewswire
- Rhythm's Incivri Launch Faces Its First Real Test As Street Bets On 18% Sequential JumpEarnings Whispers
- Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call SummaryMoby
- Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingInvestor's Business Daily
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeGlobeNewswire
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 78.47%, based on analyst consensus.
When was the latest EPS estimate revision for RYTM?▾
The most recent revision occurred on 2026-11-09, when analysts adjusted the next-year EPS growth estimate from 80.94% to 78.47%.
What sector and industry does Rhythm Pharmaceuticals Inc belong to?▾
Rhythm Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RYTM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rhythm Pharmaceuticals Inc (RYTM) appears here because it was detected by our daily top-EPS-revision-performer screen.